HP
BIOR

Hound Partners’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Hound Partners’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-884
Closed -$1.99M – 114
2020
Q2 		$1.99M Buy
+884
New +$2.41M 0.18% 36

Other funds holding BIOR

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Hound Partners's BIOR Position: Q3 2020 in Review

Hound Partners sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q3 2020, closing a stake of 884 shares — an estimated $1.99M sold.

Hound Partners first reported a position in BIOR in Q2 2020 and held it in 1 quarter. The position peaked at $1.99M in Q2 2020. 39 funds tracked by Wall St. Rank hold BIOR as of Q3 2020.

  • Hound Partners reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Hound Partners sold 884 Biora Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $1.99M.
  • Hound Partners first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Hound Partners's Biora Therapeutics, Inc. Common Stock position peaked at $1.99M in Q2 2020.
  • 39 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Hound Partners's 13F filing for Q3 2020, filed 16 Nov 2020.